ABC Arbitrage SA Takes Position in CVS Health Corporation $CVS

ABC Arbitrage SA bought a new position in shares of CVS Health Corporation (NYSE:CVS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,343 shares of the pharmacy operator’s stock, valued at approximately $384,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Sei Investments Co. boosted its holdings in shares of CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after buying an additional 134,535 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of CVS Health by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares during the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after purchasing an additional 7,588 shares during the period. HUB Investment Partners LLC lifted its stake in CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after purchasing an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 0.2%

Shares of NYSE CVS opened at $106.11 on Wednesday. The stock has a market capitalization of $135.39 billion, a P/E ratio of 46.74, a PEG ratio of 1.04 and a beta of 0.61. The stock’s fifty day moving average is $97.87 and its 200 day moving average is $84.60. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $106.93. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the prior year, the company posted $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.5%. CVS Health’s dividend payout ratio is presently 117.18%.

Insiders Place Their Bets

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

CVS has been the topic of a number of recent analyst reports. Cantor Fitzgerald boosted their price target on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. DA Davidson lifted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their target price on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Robert W. Baird increased their price target on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, HSBC reaffirmed a “hold” rating and set a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Twenty-one investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.04.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised CVS Health’s price target to $118 from $108 and kept a buy rating, signaling more upside from current levels.
• Positive Sentiment: CVS Caremark announced an agreement with the FTC that it says will improve transparency and affordability in prescription drug pricing, which may help reduce regulatory overhang and support investor confidence. Article Title
• Positive Sentiment: Management also highlighted GLP-1 support expansion across CVS pharmacies, MinuteClinic, and virtual channels, which could strengthen its healthcare services offering and drive more consumer traffic. Article Title
• Neutral Sentiment: Commentary from Jim Cramer and several value-oriented articles reinforced the view that CVS remains a popular large-cap healthcare stock, but these pieces are more sentiment-driven than fundamentally new.
• Negative Sentiment: The FTC settlement also underscores continued scrutiny of CVS Caremark’s rebate and pricing practices, including changes to how it handles drug rebates and future TrumpRx deductible credits, which could pressure margins or business terms over time. Article Title

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.